<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01722149</url>
  </required_header>
  <id_info>
    <org_study_id>FAPME-1</org_study_id>
    <nct_id>NCT01722149</nct_id>
  </id_info>
  <brief_title>Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase I Study for the Adoptive Transfer of Re-directed FAP-specific T Cells in the Pleural Effusion of Patients With Malignant Pleural Mesothelioma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MPM patients are not eligible for surgical procedures like decortication or&#xD;
      pleuro-pneumectomy and have a median survival of 12 months with palliative chemotherapy.&#xD;
      Therefore, new therapeutic approaches are of crucial need in this clinical situation. This is&#xD;
      a phase I trial for patients with malignant pleural mesothelioma with pleural effusion&#xD;
      testing the safety of a fixed single dose of 1x10e6 adoptively transferred FAP-specific&#xD;
      re-directed T cells given directly in the pleural effusion. Lymphocytes will be taken 21 days&#xD;
      before transfer from peripheral blood. CD8 positive T cells will be isolated and&#xD;
      re-programmed by retroviral transfer of a chimeric antigen receptor (CAR) recognizing FAP&#xD;
      which serves as target structure in MPM.&#xD;
&#xD;
        -  Trial with immunomodulatory product / biological&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I trial for patients with malignant pleural mesothelioma. A fixed single dose&#xD;
      of adoptively transferred FAP-specific CD8 positive re-directed T cells will be given in the&#xD;
      pleural effusion.&#xD;
&#xD;
      Three patients who are at the time point of screening not operable will be treated with&#xD;
      re-directed T cells administered into the pleural effusion after completion of 3 cycles of&#xD;
      palliative chemotherapy. In the case of one AE grade III/IV or one SAE - and the occurrence&#xD;
      of DLT both judged to be treatment related by an independent safety monitoring board - the&#xD;
      patient number will be expanded to 6 patients. The study will be stopped if one additional&#xD;
      DLT occurs also judged to be treatment related.&#xD;
&#xD;
      Patients will be treated with 1x10e6 re-directed FAP-specific T cells injected in the pleural&#xD;
      effusion. The study ends 35 days after adoptive T cell transfer. Re-directed FAP-specific T&#xD;
      cells will be administered at day 0 (day 14 of the third cycle of palliative chemotherapy).&#xD;
      The study is designed to demonstrate safety of 1x10e6 re-directed FAP-specific T cells. The&#xD;
      next patient will be enrolled earliest, when the previous patient completed day +14 and the&#xD;
      safety monitoring board has not declared any DLTs. The palliative chemotherapy is not part of&#xD;
      the study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2015</start_date>
  <completion_date type="Actual">July 18, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Adoptive Transfer of re-directed FAP-specific T cells</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>until 35 days after transfer of re-directed T cells</time_frame>
    <description>Incidence and severity of treatment-related laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version v4.03 criteria as grade III-IV. In the case of one AE grade III/IV or one SAE the safety monitoring board will judge whether the case is treatment related and whether it have to be counted as DLT.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Adoptive Transfer of re-directed T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Adoptive Transfer of re-directed T cells</intervention_name>
    <description>Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion</description>
    <arm_group_label>Adoptive Transfer of re-directed T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed and documented malignant pleural&#xD;
             mesothelioma with pleural effusion,&#xD;
&#xD;
          -  Signed Informed Consent after being informed,&#xD;
&#xD;
          -  Patients medically and/or functionally at screening not accessible for surgical&#xD;
             treatment&#xD;
&#xD;
          -  Bone marrow function: hemoglobin &gt;/= 100 g/L; white blood cell count (WBC) &gt;/= 1.0 x&#xD;
             109/L; absolute neutrophile count (ANC) &gt;/= 0.5 x 109/L; platelet count &gt;/= 100 x&#xD;
             109/L,&#xD;
&#xD;
          -  Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) &lt;/= 2.5 times&#xD;
             upper limit of normal (ULN)); bilirubin &lt;/= 1.5 x ULN,&#xD;
&#xD;
          -  Renal: creatinine = 176 umol/l and creatinine clearance = 45 mL/min,&#xD;
&#xD;
          -  No concomitant treatment with systemic corticosteroids, or any other immunosuppressive&#xD;
             agents,&#xD;
&#xD;
          -  The patient has received no major organ allograft,&#xD;
&#xD;
          -  HIV-negative,&#xD;
&#xD;
          -  HBV and HCV negative,&#xD;
&#xD;
          -  No uncontrolled bleeding disorder,&#xD;
&#xD;
          -  Patients of child-producing potential must agree to use contraception while enrolled&#xD;
             in the study and for 24 months after the adoptive transfer.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Contra-indications to the class of TpP, e.g. known hypersensitivity or allergy to the&#xD;
             investigational product,&#xD;
&#xD;
          -  Contra-indications on ethical grounds,&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  Lack of safe contraception: Safe contraception is defined as follows:Female and male&#xD;
             subjects of childbearing potential, using and willing to continue using a medically&#xD;
             reliable method of double barrier contraception for the entire study duration and the&#xD;
             next 2 years, such as oral, injectable, or implantable contraceptives, or intrauterine&#xD;
             contraceptive devices in combination with preservatives. Or subjects who are using any&#xD;
             other method considered sufficiently reliable by the investigator in individual&#xD;
             cases.Subjects who are surgically sterilized/hysterectomized or post-menopausal for&#xD;
             longer than 2 years are not considered as being of child bearing potential.&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse&#xD;
&#xD;
          -  Pericardial effusion of more than 100 ml. Pericardial involvement assessed by CT scan&#xD;
&#xD;
          -  Patients with medical history of coronary heart disease (CHD), stroke or peripheral&#xD;
             vascular disease (PVD),&#xD;
&#xD;
          -  Patients with medical history of autoimmune disease such as multiple sclerosis, lupus,&#xD;
             rheumatoid arthritis, inflammatory bowel disease or small vessel vasculitis,&#xD;
&#xD;
          -  Regular intake of immune-modulating drugs,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia or confusional state of the subject,&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study,&#xD;
&#xD;
          -  Previous enrolment into the current study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Curioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Oncology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, JÃ¼ngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013 Aug 12;11:187. doi: 10.1186/1479-5876-11-187.</citation>
    <PMID>23937772</PMID>
  </reference>
  <reference>
    <citation>Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012 Dec 22;12:615. doi: 10.1186/1471-2407-12-615.</citation>
    <PMID>23259649</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2012</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant pleural mesothelioma</keyword>
  <keyword>re-directed T cells</keyword>
  <keyword>FAP</keyword>
  <keyword>fibroblast activation protein</keyword>
  <keyword>CD8 positive T cells</keyword>
  <keyword>pleural effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

